Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in the Treatment of Pulmonary Arterial Hypertension
NCT05679570Phase 2Completed
- Sponsor
- International University of Health and Welfare
- Start
- Jul 2022
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of satralizumab in pulmonary arterial hypertension (PAH), sponsored by International University of Health and Welfare. Started Jul 2022; status: completed.
02
Drugs
satralizumab
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05679570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679570.